🚀 VC round data is live in beta, check it out!
Tanvex BioPharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tanvex BioPharma and similar public comparables like Editas Medicine, Silence Therapeutics, SIGA Technologies, Nextbiomedical Co and more.
Tanvex BioPharma Overview
About Tanvex BioPharma
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from USA, also operates in Taiwan too.
Founded
2013
HQ
Employees
133
Website
Sectors
Financials (FY)
EV
$366M
Tanvex BioPharma Financials
Tanvex BioPharma reported last fiscal year revenue of $13M and negative EBITDA of ($35M).
In the same fiscal year, Tanvex BioPharma generated ($14M) in gross profit, ($35M) in EBITDA losses, and had net loss of ($48M).
Tanvex BioPharma P&L
In the most recent fiscal year, Tanvex BioPharma reported revenue of $13M and EBITDA of ($35M).
Tanvex BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $13M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($14M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (110%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($35M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (272%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (345%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($48M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (374%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tanvex BioPharma Stock Performance
Tanvex BioPharma has current market cap of $344M, and enterprise value of $366M.
Market Cap Evolution
Tanvex BioPharma's stock price is $1.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $366M | $344M | 0.8% | XXX | XXX | XXX | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTanvex BioPharma Valuation Multiples
Tanvex BioPharma trades at 28.8x EV/Revenue multiple, and (10.6x) EV/EBITDA.
Tanvex BioPharma Financial Valuation Multiples
As of April 19, 2026, Tanvex BioPharma has market cap of $344M and EV of $366M.
Equity research analysts estimate Tanvex BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tanvex BioPharma has a P/E ratio of (7.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $344M | XXX | $344M | XXX | XXX | XXX |
| EV (current) | $366M | XXX | $366M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 28.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (26.2x) | XXX | XXX | XXX |
| P/E | — | XXX | (7.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tanvex BioPharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tanvex BioPharma Margins & Growth Rates
Tanvex BioPharma's revenue in the last fiscal year grew by 1056%.
Tanvex BioPharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Tanvex BioPharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 1056% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (272%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 79% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 127% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 235% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tanvex BioPharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tanvex BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Editas Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Silence Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SIGA Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Nextbiomedical Co | XXX | XXX | XXX | XXX | XXX | XXX |
| Anavex Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tanvex BioPharma M&A Activity
Tanvex BioPharma acquired XXX companies to date.
Last acquisition by Tanvex BioPharma was on XXXXXXXX, XXXXX. Tanvex BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tanvex BioPharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTanvex BioPharma Investment Activity
Tanvex BioPharma invested in XXX companies to date.
Tanvex BioPharma made its latest investment on XXXXXXXX, XXXXX. Tanvex BioPharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tanvex BioPharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tanvex BioPharma
| When was Tanvex BioPharma founded? | Tanvex BioPharma was founded in 2013. |
| Where is Tanvex BioPharma headquartered? | Tanvex BioPharma is headquartered in United States. |
| How many employees does Tanvex BioPharma have? | As of today, Tanvex BioPharma has over 133 employees. |
| Is Tanvex BioPharma publicly listed? | Yes, Tanvex BioPharma is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Tanvex BioPharma? | Tanvex BioPharma trades under 6541 ticker. |
| When did Tanvex BioPharma go public? | Tanvex BioPharma went public in 2015. |
| Who are competitors of Tanvex BioPharma? | Tanvex BioPharma main competitors are Editas Medicine, Silence Therapeutics, SIGA Technologies, Nextbiomedical Co. |
| What is the current market cap of Tanvex BioPharma? | Tanvex BioPharma's current market cap is $344M. |
| What is the current revenue of Tanvex BioPharma? | Tanvex BioPharma's last fiscal year revenue is $13M. |
| What is the current EV/Revenue multiple of Tanvex BioPharma? | Current revenue multiple of Tanvex BioPharma is 28.8x. |
| Is Tanvex BioPharma profitable? | No, Tanvex BioPharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.